Distinct approaches to investigate the importance of the murine 4-1BB 4-1BBL interaction in the antibody response to Streptococcus pneumoniae.
Protection against infection with Streptococcus pneumoniae is based mainly on the generation of antibodies to the pneumococcal capsular polysaccharides (caps-PS). Although caps-PS are considered thymus-independent antigens, there is a growing body of evidence that T lymphocytes and costimulatory molecules are involved in the regulation of the antibody response to caps-PS. We investigated whether the interaction between 4-1BB and 4-1BB ligand (4-1BBL) is involved in the modulation of the antibody response to caps-PS after immunization with Pneumovax or with intact heat-killed S. pneumoniae. Treatment with agonistic anti-4-1BB mAb, which mimics engagement of 4-1BB by 4-1BBL, had no effect on the IgG and IgM immune response to caps-PS (Serotype 3) after immunization with Pneumovax or with S. pneumoniae Serotype 3. However, anti-4-1BB treatment strongly inhibited the IgG response to pneumococcal surface protein A (PspA). By contrast, the IgG anti-caps-PS (Serotype 3) antibody response was reduced strongly in 4-1BBL(-/-) mice immunized with S. pneumoniae Serotype 3. The IgG anti-PspA antibody response in the 4-1BB(-/-) mice was comparable with the immune response in the wild-type mice. We conclude that distinct pathways are involved in the humoral antibody response to pneumococcal antigens, depending on the nature of the antigen and the context in which the different antigens are presented. The 4-1BB-4-1BBL interaction is not involved in the antibody response to soluble caps-PS. The influence of the 4-1BB-4-1BBL interaction in the immune reaction to S. pneumoniae Serotype 3 depends on the experimental system used.
Moens
Leen
L
Department of Molecular Cell Biology, Faculty of Medicine, Catholic University Leuven, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.
Jeurissen
Axel
A
Mittler
Robert S
RS
Wuyts
Greet
G
Michiels
George
G
Boon
Louis
L
Ceuppens
Jan L
JL
Bossuyt
Xavier
X
D053330:4-1BB Ligand / Q000235:genetics / Q000502:physiology*; D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D000917:Antibody Formation; D000942:Antigens, Bacterial / Q000276:immunology; D016667:Bacterial Capsules / Q000276:immunology; D001426:Bacterial Proteins / Q000276:immunology / Q000378:metabolism*; D005786:Gene Expression Regulation; D007114:Immunization; D007074:Immunoglobulin G / Q000276:immunology / Q000378:metabolism; D007075:Immunoglobulin M / Q000276:immunology / Q000378:metabolism; D008024:Ligands; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011008:Pneumococcal Infections / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000276:immunology / Q000378:metabolism; D013296:Streptococcus pneumoniae / Q000276:immunology* / Q000472:pathogenicity; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9 / Q000235:genetics / Q000502:physiology*
D053330:4-1BB Ligand; D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008024:Ligands; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9; C051592:pneumococcal surface protein A